Core Insights - Cadrenal Therapeutics is advancing CAD-1005 as a lead development priority for treating heparin-induced thrombocytopenia (HIT), supported by encouraging Phase 2 data and recent FDA feedback [1][3] - The company is also exploring broader opportunities within its 12-LOX inhibitor platform for future value creation [1][3] Recent Highlights - CAD-1005 demonstrated a greater than 25% absolute reduction in thrombotic events compared to placebo in a Phase 2 study, indicating its potential as a differentiated treatment for HIT [7] - The End-of-Phase 2 meeting with the FDA clarified the regulatory path for CAD-1005, with the company currently incorporating FDA feedback into the Phase 3 trial protocol [7][3] Financial Performance - For Q4 2025, research and development expenses were $0.7 million, down from $1.5 million in Q4 2024, while general and administrative expenses decreased to $2.4 million from $2.7 million [4] - The net loss for Q4 2025 was $3.0 million, an improvement from a net loss of $4.2 million in the same quarter of 2024 [4] Cash Position - As of December 31, 2025, Cadrenal had cash and cash equivalents of $4.0 million, down from $10.0 million in 2024, and is evaluating financing options to support clinical development activities [5][12] Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on novel therapies for life-threatening immune and thrombotic conditions, with CAD-1005 being its first-in-class 12-LOX inhibitor [8] - The company also has a broader pipeline that includes tecarfarin and frunexian, targeting chronic anticoagulation and acute hospital settings, respectively [9]

Summary of Cadrenal Therapeutics Conference Call Company Overview - **Company**: Cadrenal Therapeutics (NasdaqCM: CVKD) - **Focus**: Development of CAD-1005, an IV solution for treating heparin-induced thrombocytopenia (HIT) and other potential indications Key Points Industry and Product Development - **Recent Development**: Cadrenal has in-licensed CAD-1005, previously known as VLX-1005, which is ready to move into phase III development [2] - **Phase II Completion**: CAD-1005 has completed phase II trials, showing promising results in reducing thrombotic events in patients with HIT [4][5] - **Mechanism of Action**: CAD-1005 works by inhibiting 12-lipoxygenase, addressing the underlying platelet activation in HIT, unlike existing therapies that only treat the symptoms [9][10] Clinical Insights - **Patient Context**: HIT occurs in patients undergoing cardiac surgery who receive heparin, leading to a paradoxical increase in blood clots due to an immune reaction [3][39] - **Safety Profile**: The drug has shown no extra bleeding in phase I and phase II trials, which is a critical concern for anticoagulants [13] - **Primary Endpoint for Phase III**: The primary endpoint will focus on the reduction of thrombotic events, with a therapy duration of 7-14 days [19][21] Regulatory and Market Position - **FDA Designations**: CAD-1005 has received Orphan Drug status and Fast Track designation from the FDA, indicating a significant unmet medical need [5][18] - **Market Potential**: The estimated market for CAD-1005 is projected to be around $850 million in the U.S. and EU for HIT, which has not seen a new drug for decades [37] Future Directions - **Phase III Trial Design**: The trial will include a powered superiority analysis against placebo and will involve academic centers experienced in treating HIT [27][19] - **Funding Strategy**: The phase III program is estimated to cost between $35-$40 million and is expected to last about 24 months [36] - **Long-term Vision**: Success for Cadrenal includes submitting a New Drug Application (NDA) within three years and advancing their oral series, CAD-2000, into phase III for chronic indications like type 1 and type 2 diabetes [44][45] Additional Indications - **Potential Uses Beyond HIT**: CAD-1005 may also be effective in treating obesity and type 1 and type 2 diabetes, with ongoing research to explore these applications [10][42][43] Conclusion - **Strategic Focus**: Cadrenal is concentrating on HIT as the primary indication while also exploring other potential uses for CAD-1005, aiming for a strong market entry and subsequent expansion into other therapeutic areas [41][45]

Core Insights - Cadrenal Therapeutics, Inc. is advancing its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, which targets inflammatory consequences of obesity and Type 2 diabetes [1][2] Group 1: Scientific Findings - Recent studies indicate that CAD-1005 can delay the onset of autoimmune diabetes in non-obese diabetic mice, highlighting 12-LOX as a significant factor in obesity-related inflammation [2] - In preclinical models, CAD-1005 has shown therapeutic benefits such as improved glycemic control, reduced pancreatic β-cell loss, and lower levels of pro-inflammatory cytokines in adipose tissues [2][4] - The mechanism of 12-LOX inhibition acts as a selective "switch" to deactivate inflammatory pathways, restoring healthy metabolic signaling and protecting tissues from damage [2] Group 2: Clinical Development - CAD-1005 is also being evaluated for Heparin-Induced Thrombocytopenia (HIT), with a recent Phase 2 trial showing a reduction in thrombotic events in patients [4][7] - The drug has received Orphan Drug Designation and Fast Track designation from the U.S. FDA, as well as orphan drug status from the European Medicines Agency [7][8] Group 3: Competitive Advantage - Unlike existing treatments for obesity and diabetes, CAD-1005 specifically targets inflammatory signals in adipose tissues and the pancreas, which are key drivers of metabolic disorders [3][6] - Cadrenal believes that CAD-1005 is the only product in clinical development utilizing this mechanism to inhibit adipo-inflammatory signaling, potentially enhancing the effects of existing GLP-1 obesity medications [3][4] Group 4: Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions [8] - The company's broader pipeline includes tecarfarin, an oral vitamin K antagonist, and frunexian, a Factor XIa inhibitor for acute hospital settings [9]

Core Insights - Cadrenal Therapeutics is advancing its lead program, CAD-1005, a selective 12-LOX inhibitor, targeting heparin-induced thrombocytopenia (HIT) with promising Phase 2 study results [2][5] - The company has expanded its pipeline to include additional 12-LOX inhibitors, indicating potential applications in both acute and chronic inflammatory and thrombotic conditions [4][9] - The upcoming End-of-Phase 2 (EOP-2) meeting with the FDA is a critical milestone for CAD-1005, which has already received Orphan Drug Designation and Fast Track designation [7][9] Company Overview - Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing therapies for life-threatening immune and thrombotic disorders [9] - The company’s lead product, CAD-1005, is the first selective 12-LOX inhibitor to reach clinical-stage development, addressing the underlying causes of HIT rather than just its symptoms [7][9] - The broader pipeline includes tecarfarin, an oral vitamin K antagonist for patients with end-stage kidney diseases, and frunexian, a parenteral Factor XIa inhibitor for acute hospital settings [10] Market Potential - The therapeutic areas targeted by Cadrenal's 12-LOX inhibitors represent multi-billion-dollar global markets, with opportunities to improve patient outcomes in various high-impact disease areas [4][3] - Scientific research supports the role of 12-LOX in several conditions, including atherosclerosis, vascular inflammation, and immune-mediated metabolic disorders, indicating a wide range of potential applications for the company's inhibitors [3][4]

Core Insights - Cadrenal Therapeutics is addressing the unmet medical need in heparin-induced thrombocytopenia (HIT) with its investigational drug candidate VLX-1005, which is the first and only potent, highly selective 12-LOX inhibitor in clinical testing [1][3][10] Company Developments - Cadrenal acquired VLX-1005 in December 2025, recognizing its potential to transform treatment for HIT and other immune-mediated thrombotic disorders [2] - The company is rapidly engaging with the U.S. Food and Drug Administration (FDA) to discuss the design of a potential pivotal Phase 3 registration study for VLX-1005 in HIT [9] Clinical Insights - Emerging data from a Phase 2 clinical trial suggest that VLX-1005 may reduce thrombotic complications, indicating its potential as a novel therapy that targets immune thrombotic drivers rather than just suppressing coagulation [3][4] - Recent findings highlight the high incidence and clinical burden of thrombotic complications in HIT, emphasizing the limitations of existing therapies that do not directly modulate platelet immune responses [5] Scientific Background - 12-lipoxygenase (12-LOX) has been identified as a key mediator of platelet activation and immune thrombotic responses, making it a compelling therapeutic target [6] - VLX-1005 is designed to selectively modulate immune-mediated platelet activation while minimizing off-target effects, representing a significant advancement in the development of 12-LOX inhibitors [8] Regulatory Status - VLX-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the FDA, as well as orphan drug status from the European Medicines Agency [10]

Core Insights - Cadrenal Therapeutics, Inc. is focused on developing transformative therapeutics to address limitations in current anticoagulation therapy, particularly for rare and high-risk patient populations [1][2] Company Overview - Cadrenal Therapeutics is engaged in the $40 billion anticoagulation market, aiming to bridge critical gaps in acute and chronic anticoagulation management [2] - The company has three clinical-stage assets: - VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with heparin-induced thrombocytopenia (HIT) [4][6] - Tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), currently Phase 3-ready [4][6] - Frunexian, a parenteral small-molecule Factor XIa antagonist for acute hospital settings, currently Phase 2-ready [4][6] Upcoming Events - The management team, including CEO Quang X. Pham, will hold partnering and investor meetings during the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, CA [1][2] Strategic Focus - The company aims to develop novel, differentiated products that address significant gaps in anticoagulation management for specific patient populations [2][4]

Core Viewpoint - Cadrenal Therapeutics is positioned in a niche market that is significantly underserved, focusing on developing innovative anticoagulants for difficult-to-treat patient populations, particularly those with end-stage kidney disease and atrial fibrillation [1][2]. Company Developments - The company has made strides in manufacturing readiness, enhanced its leadership team, and expanded its pipeline, notably through the acquisition of VLX-1005, a Phase 2 program for Heparin-Induced Thrombocytopenia (HIT), which is expected to enhance its strategic position [3][5]. - Cadrenal is transitioning from a single-asset microcap to a multi-faceted clinical platform within the $40 billion anticoagulation market, with the Factor XIa portfolio opening opportunities in acute hospital settings [4][6]. Market Position and Valuation - Despite the expansion of its portfolio, the market continues to undervalue Cadrenal, treating it as a single-asset company rather than recognizing its diverse clinical approaches and potential catalysts [6][7]. - The company is on the verge of significant milestones, with tecarfarin nearing Phase 3 trial readiness and VLX-1005 entering a critical phase for clinical data, which could lead to a reevaluation of its market position [8][9]. Future Outlook - The current period may be the last opportunity for investors to underestimate Cadrenal, as the company is preparing for impactful milestones that could shift market perception from overlooked to obvious [9].

Core Insights - Cadrenal Therapeutics has acquired VLX-1005 and related 12-LOX assets from Veralox Therapeutics, enhancing its pipeline with a late-stage drug candidate aimed at the $40 billion global anticoagulation market [1][4] Company Overview - Cadrenal Therapeutics is focused on developing innovative therapeutics to address gaps in anticoagulation management for high-risk patient populations, with three clinical-stage assets including VLX-1005, tecarfarin, and frunexian [6] Product Details - VLX-1005 is a selective small-molecule inhibitor of 12-LOX, targeting immune platelet-mediated inflammation and addressing heparin-induced thrombocytopenia (HIT), which affects up to 5% of patients exposed to heparin [2][8] - The drug has received Orphan Drug Designation and Fast Track designation from the FDA, indicating its potential significance in treating rare conditions [4][8] Clinical Development - Phase 1 studies of VLX-1005 showed it was well tolerated with no serious adverse events, while a Phase 2 study indicated promising reductions in thromboembolic events among patients with suspected HIT [3][4] - The market for HIT treatment is estimated to reach $1 billion in the US and EU, highlighting the commercial potential of VLX-1005 [5] Acquisition Terms - The acquisition agreement includes upfront and milestone payments to Veralox contingent on future clinical and regulatory achievements, as well as royalties on global sales of VLX-1005 [5]

Core Insights - Cadrenal Therapeutics, Inc. has appointed Dr. Lee Scott Golden as an independent director to its Board of Directors, effective immediately [1][3] - Dr. Golden brings over 25 years of experience in the biopharmaceutical industry, particularly in cardiovascular medicine and anticoagulation therapy [2][3] - The company aims to develop novel anticoagulants to address significant unmet needs in both acute and chronic anticoagulation therapy [4] Company Overview - Cadrenal Therapeutics focuses on developing innovative biopharmaceutical products that improve anticoagulation therapy by providing greater predictability, stability, and fewer bleeding complications [4] - The company currently has two clinical-stage assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for acute hospital settings [4] - The mission is to reshape standards of care in anticoagulation by targeting underserved patient populations [4]

Core Insights - Cadrenal Therapeutics, Inc. has been recognized for its leadership in the biopharmaceutical sector, particularly in anticoagulation therapy, with CEO Quang X. Pham receiving the "Executive of the Year Award" from BioFlorida [1][3] Company Overview - Cadrenal Therapeutics is focused on developing innovative biopharmaceutical products aimed at addressing significant gaps in both acute and chronic anticoagulation therapy [4] - The company is advancing two clinical-stage assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for acute hospital settings [4] - Cadrenal aims to reshape standards of care in anticoagulation by targeting underserved patient populations and enhancing the predictability, stability, and control of anticoagulant therapies [4] Industry Context - BioFlorida represents a broad spectrum of organizations within Florida's life-science ecosystem, including biotechnology and medical technology, and is dedicated to fostering innovation and economic growth in the sector [2]